Pharmaceuticals

G-CSF (Granulocyte Colony Stimulating Factors) Market Future Outlook: Strong Growth Expected Toward $12.21 Billion by 2030

February 16, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the g-csf (granulocyte colony stimulating factors) market from 2026–2035 with trusted insights from The Business Research Company

Starting from its 2026 valuation, what market size is the G-CSF (Granulocyte Colony Stimulating Factors) Market expected to reach by 2030?

The g-csf (granulocyte colony stimulating factors) market has shown consistent expansion in recent years. It is anticipated to increase from $9.48 billion in 2025 to $9.94 billion in 2026, at a compound annual growth rate (CAGR) of 4.8%. The historical growth can be attributed to several factors including the restricted access to g-csf therapies, the rising occurrence of chemotherapy-induced neutropenia, an expanding population of oncology patients, regulatory approvals granted for initial g-csf products, and the widespread adoption of injectable formulations.

The market for g-csf (granulocyte colony stimulating factors) is projected to experience robust expansion over the coming years. This market is anticipated to reach $12.21 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.3%. Factors contributing to this anticipated growth include the introduction of new g-csf products, the spread of biosimilars into developing regions, a rise in the application of combination therapies, escalating demand for pre-filled syringe formats, and increased spending on supportive care and initiatives for neutropenia management. Key trends expected during this period involve an escalating preference for g-csf biosimilars, greater acceptance of pre-filled syringes and injectable formats, an increase in combination therapies incorporating other growth factors, wider application of g-csf in cancer and blood disorder treatments, and enhanced understanding of neutropenia management and supportive care.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3466&type=smp

What Drivers Are Driving Adoption Within The G-CSF (Granulocyte Colony Stimulating Factors) Market?

The growing incidence of cancer is projected to boost the G-CSF (granulocyte colony stimulating factor) market in the future. Cancer is a condition marked by the uncontrolled multiplication and spread of abnormal cells, which can impair standard bodily functions and lead to death. The increase in cancer prevalence is driven by factors such as aging populations, changes in lifestyle, and environmental exposures that raise cancer risk. The G-CSF market addresses this by offering growth factors that stimulate the production of white blood cells, thereby mitigating the chance of infection and sepsis in cancer patients receiving chemotherapy. For instance, according to the National Health Service (NHS), a UK-based government health agency, there were 354,820 new cancer diagnoses in 2023, averaging 972 per day, which was 8,605 more than in 2022, as reported in October 2025. Hence, the rising occurrence of cancer is a key driver for the growth of the G-CSF (granulocyte colony stimulating factor) market.

What Segments Are Included Within The G-CSF (Granulocyte Colony Stimulating Factors) Market?

The g-csf (granulocyte colony stimulating factors) market covered in this report is segmented –

1) By Type: Pegfilgrastim, Lenograstim, Filgrastim, Other Types

2) By Product Form: Tablet, Capsule, Other Product Forms

3) By Application: Oncological Diseases, Blood Disorders, Chronic And Autoimmune Disorders, Other Applications

Subsegments:

1) By Pegfilgrastim: Pre-filled Syringes, Vial Formulations, Biosimilars Of Pegfilgrastim

2) By Lenograstim: Injectable Formulations, Vial Formulations, Combination Therapies

3) By Filgrastim: Injectable Formulations, Pre-filled Syringes, Biosimilars Of Filgrastim

4) By Other Types: Filgrastim-sndz (Biosimilar), Novel G-CSF Products In Development, Combination Therapies With Other Growth Factors

Which Trends Are Guiding The Evolution Of The G-CSF (Granulocyte Colony Stimulating Factors) Market?

Major companies engaged in the G-CSF (granulocyte colony stimulating factor) market are prioritizing technological advancements in hematopoietic therapies, particularly through dimeric fusion protein design to improve neutrophil production and minimize immunogenicity in long-acting G-CSF treatments. Dimeric fusion protein design entails linking two G-CSF molecules into a unified protein to prolong its half-life and enhance receptor activation without the need for PEGylation. For instance, in November 2023, Evive Biotech Inc., a biopharmaceutical company based in Singapore, obtained U.S. Food and Drug Administration (FDA) approval for Ryzneuta (efbemalenograstim alfa), a long-acting biosimilar G-CSF developed to shorten the duration of neutropenia and febrile neutropenia in adults undergoing cytotoxic chemotherapy. Ryzneuta, a modified recombinant G-CSF, works by stimulating neutrophil generation in the bone marrow, thereby accelerating the recovery of neutrophil counts. Its notable features include extended dosing intervals, compatibility with diverse chemotherapy regimens, and a convenient prefilled syringe ready for use. It is prescribed for the prophylaxis of chemotherapy-induced neutropenia, stem cell mobilization, and supportive care for immunocompromised patients, offering benefits like fewer injections, enhanced adherence, and better overall patient outcomes.

Who Are The Top-Performing Companies In The G-CSF (Granulocyte Colony Stimulating Factors) Market In Recent Years?

Major companies operating in the g-csf (granulocyte colony stimulating factors) market are Amgen Inc., Coherus Biosciences Inc., Sandoz, Biocon/Mylan, Teva Pharmaceuticals Inc., Chugai Pharma, Intalfarmaco Group, Pfizer, Sun Pharmaceutical Industries Limited, Cipla.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report

Which Region Currently Holds The Largest Share Of The G-CSF (Granulocyte Colony Stimulating Factors) Market?

North America was the largest region in the G-CSF (granulocyte colony-stimulating factors) market in 2025. The regions covered in the g-csf (granulocyte colony stimulating factors) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized G-CSF (Granulocyte Colony Stimulating Factors) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3466&type=smp

Browse Through More Reports Similar to the Global G-CSF (Granulocyte Colony Stimulating Factors) Market 2026, By The Business Research Company

Therapeutic Proteins Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-proteins-global-market-report

Thyroid Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795